

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





CD3 epsilon antibody [145-2C11]

Cat. No. GTX14351

| Host | Armenian Hamster |
|-------------|--|
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Application | WB, ICC/IF, IHC-Fr, FACS, IP, Activation, Depletion, Neutralizing/Inhibition |
| Reactivity | Mouse |

Reference (10) **Package** 500 μα

PRODUCT

Summary

The 145-2C11 antibody is specific for mouse CD3e, also known as CD3 epsilon, a 20 kDa subunit of the T cell receptor complex, along with CD3 gamma and CD3 delta. These integral membrane protein chains assemble with additional chains of the T cell receptor (TCR), as well as CD3 zeta chain, to form the T cell receptor - CD3 complex. Together with co-receptors CD4 or CD8, the complex serves to recognize antigens bound to MHC molecules on antigen-presenting cells. Such interactions promote T cell receptor signaling (T cell activation) and can result in a number of cellular responses including proliferation, differentiation, production of cytokines or activation-induced cell death. CD3 is differentially expressed during thymocyte-to-T cell development and on all mature T cells.

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

| Suggested dilution | Recommended dilution |
|----------------------------------|----------------------|
| WB | Assay dependent |
| ICC/IF | Assay dependent |
| IHC-Fr | Assay dependent |
| FACS | Assay dependent |
| IP | Assay dependent |
| Activation | Assay dependent |
| Depletion | Assay dependent |
| Neutralizing/Inhibition | Assay dependent |
| Not tested in other applications | |

Not tested in other applications

| Calculated | MW | 21 kDa. (<u>Note</u>) |
|-------------------|----|-------------------------|
|-------------------|----|-------------------------|

Product Note

The complete 145-2C11 antibody is commonly used to stimulate T cells in vitro however, when used in vivo activation of resting T cells results in cytokine release and toxicity caused by Ab-mediated cross-linking of T cells and Fcy receptorbearing cells. To avoid these complications non-Fc receptor binding F(ab')2 fragments of the 145-2C11 antibody are commonly used. This non-FcR-binding anti-CD3 induces apoptosis of Ag-activated T cells in vivo by allowing durable expression of the TCR and sustained signaling. Foxp3+ Tregs have been shown to be resistant to CD3 antibody-mediated depletion.



For full product information, images and publications, please visit our website.

Date 2023 / 07 / 27 Page 1 of 2



| PROPERTIES | |
|---------------|---|
| Form | Liquid |
| Buffer | 10mM NaH ₂ PO ₄ (pH7.2), 150mM NaCl |
| Preservative | 0.09% Sodium azide |
| Storage | Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C. |
| Concentration | 0.5 mg/ml (Please refer to the vial label for the specific concentration.) |
| Immunogen | Mouse BM10-37 cytotoxic T cells |
| Purification | Purified by affinity chromatography From tissue culture supernatant |
| Purity | >95% (Determined by SDS-PAGE) |
| Endotoxin | <0.002EU/µg (Determined by LAL gel clotting assay) |
| Conjugation | Unconjugated |
| Note | For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption. |
| | Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product. |



For full product information, images and publications, please visit our <u>website</u>.

Date 2023 / 07 / 27 Page 2 of 2